Stanzen Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth 83.33%
- Ebitda 83.33%
- Net Worth -25.00%
- Total Assets %
About Stanzen Life Sciences
Stanzen Life Sciences Private Limited (SLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 September 2018 (Six years and four months 21 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Bhagavan Kamireddy and Nitya Kamireddy serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24299TG2018PTC127006
-
Company No.
127006
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
21 Sep 2018
-
Date of AGM
28 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Stanzen Life Sciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhagavan Kamireddy
|
Director | 21-Sep-2018 | Current |
|
Nitya Kamireddy
|
Director | 01-Jun-2023 | Current |
Financial Performance of Stanzen Life Sciences.
Stanzen Life Sciences Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 83.33% increase in profit. The company's net worth observed a substantial decline by a decrease of 25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Stanzen Life Sciences?
In 2019, Stanzen Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Stanex Drugs And Chemicals Private LimitedBhagavan Kamireddy and Nitya Kamireddy are mutual person
-
Stanex Breeding Farms Private LimitedBhagavan Kamireddy is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Stanzen Life Sciences?
Unlock and access historical data on people associated with Stanzen Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stanzen Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stanzen Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
